Ketamine 101
July 15, 2022

Ketamine for major depressive disorder and bipolar depression

Ketamine for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis.

Given the significant disability, morbidity and mortality associated with depression, the promising recent trials of ketamine highlight a novel intervention. A meta-analysis was conducted to assess the efficacy of ketamine in comparison with placebo for the reduction of depressive symptoms in patients who meet criteria for a major depressive episode. The large and statistically significant effect of ketamine on depressive symptoms supports a promising, new and effective pharmacotherapy with rapid onset, high efficacy and good tolerability.

https://pubmed.ncbi.nlm.nih.gov/28969441/

Latest articles